Schmidt, Sethi & Akmajian Blog

Deadly Pacemaker Wires

Posted by Dev Sethi | Apr 15, 2014 | 0 Comments

Nearly a quarter of a million Americans have pacemaker leads implanted in their hearts that may be defective. The leads are known as “Sprint Fidelis” leads, manufactured by Medtronic. The leads were recalled 2 years ago, but in this recall the potentially defective products have only been taken off the market, as the leads that have already been sold are implanted in patient's hearts. Replacing the leads carries a significant risk of death from the operation required to retrieve them. In the face of this quandary, evidence has surfaced indicating that as the Sprint Fidelis leads age, they are failing at a higher rate than previously expected.

According to an article published February 22, 2009 on the website for the journal Heart Rhythm, researchers analyzed the records of 3,000 patients and found that three years after implantation, only 88% of the Sprint Fidelis leads were still functioning. In a February 23, 2009 article in the New York Times, Medtronic disputed these new failure figures, and stated that 95% of the leads were still functioning after three years. Under either analysis, thousands of the leads have failed.

The Sprint Fidelis leads connect the heart to an implanted electronic defibrillator, which is designed to maintain normal heart rhythm by delivering an electric shock to the heart when a rhythm abnormality occurs. The electronic defibrillator keeps heart attacks from happening. The defect in the Sprint Fidelis leads causes the implanted defibrillator to either deliver shocks to the patient's heart when they are not needed, or (worse) fail to deliver shocks when they are needed. A number of patients have died as a result of failures of Sprint Fidelis leads, and hundreds of lawsuits have been filed against Medtronic.

Last month a Federal Judge in Minneapolis dismissed the lawsuits against Medtronic, citing “federal pre-emption” (a topic discussed in other postings on this blog). According to the New York Times article, some Congressional Democrats intend to introduce legislation to abolish federal pre-emption in medical device lawsuits and other product lawsuits. To date,the Bush administration has effectively shielded product manufacturers from lawsuits by injured consumers, but it is anticipated that the Obama administration will not continue to protect big corporate interests. At this point it is anyone's guess whether or not there will be any relief for the folks injured or killed by the Sprint Fidelis leads.

About the Author

Dev Sethi

Dev Sethi litigates and tries a wide-range of complex injury and death cases throughout Arizona. He has Martindale Hubbell's highest rating, AV, and he is listed in "Best Lawyers." Dev is also recognized as an Arizona Super Lawyer in the area of plaintiff's products liability litigation.Dev has been at the forefront of auto product defect litigation. He played a key role in uncovering the Goodyear Load Range E tire scandal and worked to hold Ford Motor Company responsible for the danger posed by their now notorious 15-passenger vans. Dev is currently representing families in product liability suits against the nation's largest corporations including General Motors, Ford, Pentair Pools and Invacare.


There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Our team works together - for you!

Our award-winning lawyers are backed by a talented, caring team of legal professionals, paralegals, bilingual assistants, notaries, and others - all dedicated to you, your case, and the compensation you deserve.

No fees and no costs until we win.

As such we always have your case and your best interest in mind. When you win, we win too by providing the best legal care possible.

Thorough investigation and preparation.

We tirelessly and thoughtfully prepare every case we represent as though it was going to trial. This lets insurance companies know that we are a force to be reckoned with. As such, we settle successfully 98% of the time.